Trial Outcomes & Findings for Gevokizumab for Active Scleritis (NCT NCT01835132)

NCT ID: NCT01835132

Last Updated: 2018-07-06

Results Overview

Scleral inflammation was graded following 10% Phenylephrine application with an ordinal scale of 0 (no scleral inflammation with complete blanching of vessels), 0.5+ (minimal/trace inflammation with localized pink appearance of the sclera around minimally dilated deep episcleral vessels), 1+ (mild inflammation with diffuse pink appearance of the sclera around mildly dilated deep episcleral vessels), 2+ (moderate inflammation with purplish pink appearance of the sclera with tortuous and engorged deep episcleral vessels), 3+ (severe inflammation with diffuse significant redness of sclera, the details of superficial and deep episcleral vessels can't be observed), and 4+ (necrotizing inflammation with diffuse redness of the sclera with scleral thinning and uveal show).

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

8 participants

Primary outcome timeframe

Baseline and Week 16

Results posted on

2018-07-06

Participant Flow

Initial Phase: All participants have injections at Baseline, Wks 4, 8, and 12 with follow up visits at Wks 2, 16, and 28. 1st Extension Phase: If improved by Wk 16, visits every 4 wks until Wk 36 and then 2 visits at Wks 40 and 52. As-needed 2nd Extension Phase: At Week 52, if eligible, may continue with injections at Wks 52, 54, 58 and 62.

Participant milestones

Participant milestones
Measure
Gevokizumab
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Initial Phase
STARTED
8
Initial Phase
COMPLETED
6
Initial Phase
NOT COMPLETED
2
1st Extension Phase
STARTED
6
1st Extension Phase
COMPLETED
6
1st Extension Phase
NOT COMPLETED
0
2nd Extension Phase - As Needed (PRN)
STARTED
3
2nd Extension Phase - As Needed (PRN)
COMPLETED
3
2nd Extension Phase - As Needed (PRN)
NOT COMPLETED
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Gevokizumab
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Initial Phase
Insufficient Therapeutic Response
2

Baseline Characteristics

Gevokizumab for Active Scleritis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Gevokizumab
n=8 Participants
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
5 Participants
n=5 Participants
Age, Categorical
>=65 years
3 Participants
n=5 Participants
Age, Continuous
59.88 years
n=5 Participants
Sex: Female, Male
Female
3 Participants
n=5 Participants
Sex: Female, Male
Male
5 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline and Week 16

Scleral inflammation was graded following 10% Phenylephrine application with an ordinal scale of 0 (no scleral inflammation with complete blanching of vessels), 0.5+ (minimal/trace inflammation with localized pink appearance of the sclera around minimally dilated deep episcleral vessels), 1+ (mild inflammation with diffuse pink appearance of the sclera around mildly dilated deep episcleral vessels), 2+ (moderate inflammation with purplish pink appearance of the sclera with tortuous and engorged deep episcleral vessels), 3+ (severe inflammation with diffuse significant redness of sclera, the details of superficial and deep episcleral vessels can't be observed), and 4+ (necrotizing inflammation with diffuse redness of the sclera with scleral thinning and uveal show).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=8 Participants
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Number of Participants With at Least a 2-step Reduction or Reduction to Grade 0 in Scleral Inflammation in the Study Eye (or Eyes), According to the National Eye Institute (NEI) Photographic Scleritis Grading System, on or Before the Week 16 Visit.
6 participants

SECONDARY outcome

Timeframe: Baseline and Week 2

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 2 Compared to Baseline
-1.00 ETDRS letters
Standard Deviation 4.42

SECONDARY outcome

Timeframe: Baseline and Week 4

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 4 Compared to Baseline
-1.78 ETDRS letters
Standard Deviation 3.23

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 8 Compared to Baseline
0.78 ETDRS letters
Standard Deviation 4.84

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 12 Compared to Baseline
0.11 ETDRS letters
Standard Deviation 3.86

SECONDARY outcome

Timeframe: Baseline and Week 16

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 16 Compared to Baseline
1.00 ETDRS letters
Standard Deviation 6.61

SECONDARY outcome

Timeframe: Baseline and Week 20

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 20 Compared to Baseline
1.33 ETDRS letters
Standard Deviation 3.64

SECONDARY outcome

Timeframe: Baseline and Week 24

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 24 Compared to Baseline
-0.67 ETDRS letters
Standard Deviation 4.47

SECONDARY outcome

Timeframe: Baseline and Week 28

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 28 Compared to Baseline
1.00 ETDRS letters
Standard Deviation 3.20

SECONDARY outcome

Timeframe: Baseline and Week 32

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=6 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 32 Compared to Baseline
3.00 ETDRS letters
Standard Deviation 3.90

SECONDARY outcome

Timeframe: Baseline and Week 36

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=6 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 36 Compared to Baseline
1.83 ETDRS letters
Standard Deviation 5.12

SECONDARY outcome

Timeframe: Baseline and Week 40

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=6 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 40 Compared to Baseline
2.67 ETDRS letters
Standard Deviation 5.39

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=6 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 52 Compared to Baseline
0.17 ETDRS letters
Standard Deviation 6.43

SECONDARY outcome

Timeframe: Baseline and Week 52A

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

This visit represents the beginning of the as-needed 2nd Extension Phase at Week 52. If eligible, participants continued with injections at Wks 52, 54, 58 and 62. Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 52A Compared to Baseline
-8.00 ETDRS letters
Standard Deviation 13.45

SECONDARY outcome

Timeframe: Baseline and Week 54

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 54 Compared to Baseline
-0.67 ETDRS letters
Standard Deviation 6.03

SECONDARY outcome

Timeframe: Baseline and Week 58

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 58 Compared to Baseline
-1.33 ETDRS letters
Standard Deviation 6.51

SECONDARY outcome

Timeframe: Baseline and Week 62

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Week 62 Compared to Baseline
-1.33 ETDRS letters
Standard Deviation 5.03

SECONDARY outcome

Timeframe: Baseline and Final Visit

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Visual Acuity in the Study Eye (or Eyes) at Final Safety Visit Compared to Baseline
-2.00 ETDRS letters
Standard Deviation 4.36

SECONDARY outcome

Timeframe: Baseline and Week 2

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 2 Compared to Baseline
0.67 mmHg
Standard Deviation 1.94

SECONDARY outcome

Timeframe: Baseline and Week 4

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 4 Compared to Baseline
0.67 mmHg
Standard Deviation 3.04

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 8 Compared to Baseline
1.11 mmHg
Standard Deviation 1.69

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 12 Compared to Baseline
1.00 mmHg
Standard Deviation 3.67

SECONDARY outcome

Timeframe: Baseline and Week 16

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 16 Compared to Baseline
1.56 mmHg
Standard Deviation 2.07

SECONDARY outcome

Timeframe: Baseline and Week 20

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 20 Compared to Baseline
1.33 mmHg
Standard Deviation 2.00

SECONDARY outcome

Timeframe: Baseline and Week 24

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Mean Change in Intraocular pressure (IOP) is measured and reported as change in IOP between baseline and 24 weeks in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 24 Compared to Baseline
0.78 mmHg
Standard Deviation 2.33

SECONDARY outcome

Timeframe: Baseline and Week 28

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 28 Compared to Baseline
1.11 mmHg
Standard Deviation 2.26

SECONDARY outcome

Timeframe: Baseline and Week 32

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=6 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 32 Compared to Baseline
2.67 mmHg
Standard Deviation 1.75

SECONDARY outcome

Timeframe: Baseline and Week 36

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=6 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 36 Compared to Baseline
2.17 mmHg
Standard Deviation 1.72

SECONDARY outcome

Timeframe: Baseline and Week 40

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=6 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 40 Compared to Baseline
0.50 mmHg
Standard Deviation 1.52

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: Eight participants were active from Baseline to Week 28. Of the eight active participants, one participant had two study eyes, and this participant was active in the study to Week 28. A total of two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=6 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 52 Compared to Baseline
1.83 mmHg
Standard Deviation 2.79

SECONDARY outcome

Timeframe: Baseline and Week 52A

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

This visit represents the beginning of the as-needed 2nd Extension Phase at Week 52. If eligible, participants continued with injections at Wks 52, 54, 58 and 62. Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 52A Compared to Baseline
-0.67 mmHg
Standard Deviation 2.08

SECONDARY outcome

Timeframe: Baseline and Week 54

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 54 Compared to Baseline
1.33 mmHg
Standard Deviation 4.16

SECONDARY outcome

Timeframe: Baseline and Week 58

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 58 Compared to Baseline
1.33 mmHg
Standard Deviation 3.21

SECONDARY outcome

Timeframe: Baseline and Week 62

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Week 62 Compared to Baseline
0.67 mmHg
Standard Deviation 1.53

SECONDARY outcome

Timeframe: Baseline and Final Visit

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

Intraocular pressure (IOP) is measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure
Gevokizumab
n=3 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Mean Change in Intraocular Pressure in the Study Eye (or Eyes) at Final Safety Visit Compared to Baseline
1.33 mmHg
Standard Deviation 2.08

SECONDARY outcome

Timeframe: Post-injection through study completion, up to 78 weeks per participant

Population: Eight participants were active from Baseline to Week 28. Of the 8 active participants, one participant had two study eyes and was active to Week 28. Two participants did not continue past Week 28 due to insufficient therapeutic response. Six participants were active from Week 32 to Week 52. Three participants were active from Week 52 to study end.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

Outcome measures

Outcome measures
Measure
Gevokizumab
n=9 eyes
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Number of Participants With Loss of ≥ 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters
0 participants

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: The exact change from Baseline to Week 52 for each participant (such as from mild to severe) cannot be quantified; therefore, we chose not to report due to the difficulty of reporting a quantitative change in each quadrant for each participant within the limited parameters allowed by PRS.

Scleral inflammation was summarized on an ordinal scale as either none, minimal/trace, mild, moderate, severe or necrotizing inflammation in the four quadrants of the study eye (superonasal \[SN\], superotemporal \[ST\], inferotemporal \[IT\], and inferonasal \[IN\]) for each participant at each visit. The exact change from Baseline to Week 52 for each participant (such as from mild to severe) cannot be quantified; therefore, we chose not to report due to the difficulty of reporting a quantitative change in each quadrant for each participant within the limited parameters allowed by PRS.

Outcome measures

Outcome data not reported

Adverse Events

Gevokizumab

Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Gevokizumab
n=8 participants at risk
Subcutaneous injection of 60 mg gevokizumab Gevokizumab: Subcutaneous injection of 60 mg gevokizumab
Gastrointestinal disorders
Abdominal pain
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
General disorders
Asthenia
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Investigations
Bacterial test
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Investigations
Biopsy skin
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Eye disorders
Corneal thinning
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Metabolism and nutrition disorders
Decreased appetite
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Nervous system disorders
Dizziness
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Skin and subcutaneous tissue disorders
Dry skin
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
General disorders
Fatigue
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Injury, poisoning and procedural complications
Foreign body in eye
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Renal and urinary disorders
Haematuria
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Investigations
Hemoglobin urine present
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Gastrointestinal disorders
Haemorrhoids
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Nervous system disorders
Headache
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Investigations
Hepatic enzyme increased
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Infections and infestations
Hordeolum
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Metabolism and nutrition disorders
Hyperlipidaemia
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Vascular disorders
Hypotension
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Infections and infestations
Infection
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Infections and infestations
Influenza
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
General disorders
Influenza like illness
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Gastrointestinal disorders
Irritable bowel syndrome
12.5%
1/8 • Number of events 3 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Injury, poisoning and procedural complications
Joint injury
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Injury, poisoning and procedural complications
Laceration
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Injury, poisoning and procedural complications
Limb injury
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Blood and lymphatic system disorders
Lymph node pain
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Injury, poisoning and procedural complications
Muscle strain
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Infections and infestations
Nasopharyngitis
12.5%
1/8 • Number of events 2 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Gastrointestinal disorders
Nausea
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Eye disorders
Ocular hyperaemia
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Skin and subcutaneous tissue disorders
Pruritis generalized
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Skin and subcutaneous tissue disorders
Rash
12.5%
1/8 • Number of events 2 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Renal and urinary disorders
Renal failure
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Eye disorders
Scleral thinning
12.5%
1/8 • Number of events 2 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Infections and infestations
Sinusitis
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Injury, poisoning and procedural complications
Tooth fracture
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Infections and infestations
Upper respiratory tract infection
25.0%
2/8 • Number of events 2 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Infections and infestations
Urinary tract infection
25.0%
2/8 • Number of events 2 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Skin and subcutaneous tissue disorders
Erythema
12.5%
1/8 • Number of events 2 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
General disorders
Injection site discomfort
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.
Injury, poisoning and procedural complications
Road traffic accident
12.5%
1/8 • Number of events 1 • Adverse events were collected from baseline until study completion, up to 78 weeks (wks) per participant. Participants in the 2nd extension phase had a final safety visit at least 16 wks following their last injection in the 2nd extension phase at Wk 62.

Additional Information

H. Nida Sen, MD, MHSc, Principal Investigator, NEI

National Institutes of Health

Phone: 301-402-3254

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place